Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Veracyte, Inc.    VCYT

VERACYTE, INC.

(VCYT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/07/2021 04/08/2021 04/09/2021 04/12/2021 04/13/2021 Date
52.16(c) 53.37(c) 52.57(c) 51.65(c) 55.04(c) Last
450 713 397 223 455 953 328 742 693 739 Volume
-5.87% +2.32% -1.50% -1.75% +6.56% Change
More quotes
Financials (USD)
Sales 2021 194 M - -
Net income 2021 -19,0 M - -
Net cash position 2021 671 M - -
P/E ratio 2021 -186x
Yield 2021 -
Sales 2022 242 M - -
Net income 2022 -12,1 M - -
Net cash position 2022 700 M - -
P/E ratio 2022 -265x
Yield 2022 -
Capitalization 3 688 M 3 688 M -
EV / Sales 2021 15,6x
EV / Sales 2022 12,3x
Nbr of Employees 320
Free-Float 96,6%
More Financials
Company
Veracyte, Inc. is a genomic diagnostics company. The Company, through its scientific platform, which utilizes ribonucleic acid (RNA), whole-transcriptome sequencing combined with machine learning, produces genomic tests. It provides various genomic tests, including Afirma Genomic Sequencing Classifier (GSC), Percepta Bronchial Genomic Classifier, Envisia Genomic Classifier and Afirma Xpression Atlas. It provides GSC... 
Sector
Biotechnology & Medical Research
Calendar
04/13 | 02:15pmPresentation
More about the company
Notations Surperformance© of Veracyte, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about VERACYTE, INC.
04/05VERACYTE, INC.  : Change in Directors or Principal Officers (form 8-K)
AQ
04/02VERACYTE  : to Present at 20th Annual Needham Virtual Healthcare Conference
BU
03/22SECTOR UPDATE : Health Care Stocks Rising Just Ahead of Monday Close
MT
03/22VERACYTE, INC.  : Change in Directors or Principal Officers (form 8-K)
AQ
03/22VERACYTE  : Appoints Muna Bhanji to Its Board of Directors
BU
03/15VERACYTE, INC.  : Completion of Acquisition or Disposition of Assets (form 8-K)
AQ
03/15VERACYTE  : Completes Acquisition of Decipher Biosciences
BU
03/10VERACYTE  : Commends New USPSTF Lung Cancer Screening Guidelines
BU
03/03VERACYTE, INC.  : Change in Directors or Principal Officers, Financial Statement..
AQ
03/03INSIDER TRENDS : Insider at Veracyte Makes Shares Sale for Tax Slowing 90-Day Bu..
MT
02/22VERACYTE  : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESU..
AQ
02/19VERACYTE  : Morgan Stanley Adjusts Price Target on Veracyte to $65 From $35, Mai..
MT
02/18VERACYTE  : to Present at 10th Annual SVB Leerink Global Healthcare Conference
BU
02/18SECTOR UPDATE : Health Care Stocks Benefit From Late Bargain Hunting
MT
02/18VERACYTE  : SVB Leerink Adjusts Veracyte's Price Target to $85 from $83, Keeps O..
MT
More news
News in other languages on VERACYTE, INC.
2020EN DIRECT DES MARCHES  : L'Oréal, Airbus, Eurofins Scientific, Crédit Agricole, ..
2020Un plan ou pas de plan sous le sapin ?
2020BAYER  : und Veracyte kooperieren bei Schilddrüsenkrebs
2020VERACYTE  : Le remboursement du test du cancer du sein Prosigna est désormais ap..
2020VERACYTE  : Prosigna-Brustkrebstest jetzt in Deutschland für die Kostenübernahme..
More news
Analyst Recommendations on VERACYTE, INC.
More recommendations
Chart VERACYTE, INC.
Duration : Period :
Veracyte, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERACYTE, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 83,40 $
Last Close Price 55,04 $
Spread / Highest target 72,6%
Spread / Average Target 51,5%
Spread / Lowest Target 18,1%
EPS Revisions
Managers and Directors
NameTitle
Bonnie H. Anderson Chairman & Chief Executive Officer
Keith Kennedy Chief Operating & Financial Officer
Richard T. Kloos Executive Medical Director
Giulia C. Kennedy Chief Scientific & Medical Officer
Fred E. Cohen Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
VERACYTE, INC.12.46%3 688
EXACT SCIENCES CORPORATION-5.70%21 644
GUARDANT HEALTH, INC.21.69%15 751
INVITAE CORPORATION-5.81%7 744
BGI GENOMICS CO., LTD.-3.86%7 743
ADAPTIVE BIOTECHNOLOGIES CORPORATION-26.62%6 041